【康泰生物：口服五价重配轮状病毒减毒活疫苗开启III期临床试验】金十数据4月9日讯，康泰生物公告，公司和全资子公司北京民海生物科技有限公司研发的口服五价重配轮状病毒减毒活疫苗（Vero细胞）已完成III期临床试验准备工作，开启III期临床试验，并于近日成功完成首例受试者入组。该疫苗适用于6周龄至32周龄婴儿，用于预防感染轮状病毒导致的婴幼儿胃肠炎，包含了国内轮状病毒导致胃肠炎的主要病毒血清型（G1、G2、G3、G4和G9）。本次疫苗研发取得了阶段性进展，将进一步丰富公司在多联多价疫苗领域的产品布局，提升公司的核心竞争力和市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.